Merus NV Stock News

Merus (MRUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Michelle Ross, StemPoint Capital CIO, joins CNBC's Halftime Report' to discuss her latest biotech pick.

Merus N.V. (MRUS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodie

Merus N.V. (MRUS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase

The average of price targets set by Wall Street analysts indicates a potential upside of 53% in Merus N.V. (MRUS). While the effectiveness of this highly sought-after metric is questionable, the posit

Merus N.V. is a biotech company developing novel bispecific antibodies, with two drugs in development for unmet needs in head and neck cancer and solid tumors. Petosemtamab, targeting EGFR and LGR5, s

Merus N.V. (MRUS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodie

Merus N.V. (MRUS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 15, 2023 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, fu

Merus stock has cooled down after a strong rally, but long-term investors are sitting on a 47% gain since January. The company's pipeline includes promising clinical assets, but sentiment towards the

Merus N.V. (MRUS) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.86. This compares to loss of $0.13 per share a year ago.

Shares of Merus NV MRUS, +3.02% rallied as much as 10% in the extended session Thursday after the pharma company said the U.S. Food and Drug Administration has granted one of its cancer treatments a b

Stock screeners can help investors identify stocks to buy based on a variety of criteria. In fact, one helpful predictor of stock price growth can be found with analyst ratings.